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INTRODUCTION
Preeclampsia is a potentially life-threatening disorder of pregnancy characterized by new-onset hypertension and proteinuria after 20 weeks gestation. It constitutes a leading cause of maternal and perinatal mortality and morbidity (1) (2) . Estimates are that as many as 75,000 women worldwide die each year from preeclampsia (3) . Treatment options are very limited and frequently require termination of the pregnancy, regardless of gestational age, accounting for ~20% of all preterm births (4) . Furthermore, infants born to preeclamptic mothers may be at an increased risk of hypertension, heart disease and diabetes beyond their being premature (5) .
While there are known risk factors for preeclampsia, it is not yet possible to precisely distinguish pregnancies destined to develop preeclampsia from those that will not. This has made prospective clinical studies large and expensive. Also, it has to some degree limited studies of early changes that may lead to preeclampsia. In the absence of a complete animal model of preeclampsia, the actual cause or causes of this disorder remains unknown. The pathogenesis is acknowledged to be complex and although incompletely understood, it is generally believed that one or more very early events in the pregnancy contribute to preeclampsia. One long held theory to explain this disease involves an incomplete remodeling of maternal spiral arteries by invasive extravillous placental trophoblast cells resulting in inadequate perfusion of the fetal-placental unit with attendant ischemia (6) (7) . Abnormal waveform patterns and an increased pulsatility index observed in uterine Doppler ultrasound studies support the concept of an underperfused fetus prior to clinically apparent preeclampsia (6, 7) . There is also evidence to suggest that biochemical changes may be seen in women who, later in the same pregnancy, develop this disease. Several other biochemical changes appear to precede by a few weeks clinically evident preeclampsia, including hypoxia-reoxygenation (8) , abnormal expression of angiogenic and anti-angiogenic factors in the maternal circulation and endothelial dysfunction with a pro-inflammatory response (9) (10) . Collectively, these data suggest that there are biochemical abnormalities that occur prior to clinically evident preeclampsia signs and symptoms. However, to date there are still no accepted, predictive biomarkers for this disease (11) (12) (13) by guest, on September 14, 2016 www.jlr.org Downloaded from despite some initial promise for a number of proposed candidates. Also currently, the specific causes (as opposed to consequences) of preeclampsia are still debated and have yet to be established.
It is now possible to survey hundreds to thousands of molecules in biological specimens in an unbiased way using mass spectrometry (MS). Proteomics is by far and away the most common of these approaches and has been employed to study several diseases, but its use to explore diagnostic or predictive biomarkers in serum is difficult due to ~30 highly abundant serum proteins that mask the vast majority of lower abundance species in serum due to ion suppression. Other methods have targeted peptides and lipids, although much less frequently in serum or plasma.
Lipids are increasingly recognized as having important biological roles or representing important biochemical correlates of clinical changes. A wide variety of human diseases are associated with aberrant lipid metabolism including Alzheimer's disease, diabetes and atherosclerosis (14) (15) (16) . Alterations in lipids may represent by-products of underlying pathophysiology but could also represent primary disease mediators. For example, arachidonic acid is a precursor for eicosanoids that have a significant role in inflammatory processes. There is evidence of changes in downstream products of arachidonic acid in preeclampsia (17) . As another example, oxidized lipid species can reflect increased reactive oxygen species (ROS) which are produced as a part of several diseases (18) (19) (20) . Therefore, there is ample reason to study lipid profiles in pregnant women at an early stage seeking predictive lipidomic biomarkers to identify patients at significant risk for preeclampsia. Consequently, a 'global' serum lipidomic approach, involving lipid extraction followed by direct injection, time-of-flight mass spectrometry was used to identify and chemically characterize predictive serum preeclamptic lipid biomarkers. We hypothesized that this approach would find individual lipids and sets of lipids that would allow for the prediction of a substantial portion of women who would later develop this disease in the same pregnancy and that the changes would provide insights into the mechanisms early in the development of preeclampsia. 
METHODS

Study population
Serum specimens used for both the discovery and confirmatory studies were obtained from the Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT and from Intermountain Health Care (Intermountain), Murray, UT. All samples were banked sera, obtained from a previously completed clinical study, "First-And Second-Trimester Evaluation of Risk" (21) .
Institutional Review Board (IRB) approval for these studies was obtained from the University of Utah, Intermountain and Brigham Young University prior to our initiating these experiments. Sera had been collected from pregnant women at 12-14 weeks gestation followed through the completion of their pregnancies. Specimens were analyzed without clinical identifiers.
A discovery cohort involved sera from 27 controls, having term, uncomplicated pregnancies and 29 cases, who developed preeclampsia later during the index pregnancy. The second confirmatory study of the promising potential lipid biomarkers from the discovery cohort involved serum from 37 cases and 43 controls, also collected at 12-14 weeks gestation. Demographic characteristics are summarized in Tables   1a and 1b 
Sample preparation
All specimens had been stored at -80 0 C until our receiving them on dry ice and were maintained at -80 o C before and after sample processing. Serum lipid extraction efficiency of five different organic extraction solutions were performed as follows: for a 200 µL sample 1)2.5 mL of 4:1 chloroform:methanol;
2) 2.5 mL of 4:1methyl-tert-butyl ether:methanol); 3) 1. and stored at -80 0 C.
Mass spectrometric analysis of the lipid extract
To a was collected over mass to charge ratios (m/z) of 100-3000 with an acquisition rate of 1 spectrum/sec.
Nebulizer gas and dry gas parameters were optimized to obtain a stable flow. The dry gas was set to 5 L/min at 325 0 C with a nebulization gas pressure of 1.03 bar. Mass Hunter-Qualitative software [Agilent Technologies] was used for data analysis. Each specimen generated a mass spectrum from which the total ion chromatogram (TIC the sum of all ion counts) from m/z 100 to 3000 was determined. A peak list having m/z values for all peaks with their abundances was generated from the mass spectrum.
To reduce analytical variability all MS peaks were normalized. samples. The ratio of the average intensity of these 7 peaks was comparable to or more consistent than the use of TIC counts for peak normalization, but avoided the occasional high TIC for a few MS runs with a high background. Therefore, the average of the combined intensity of these 7 peaks was used to normalize all peaks across the each individual mass spectrum.
For the second confirmatory study, all the samples were processed using the same method and were directly injected onto the same MS instrument at a flow rate of 10 µL/min, using a standard sprayer having an i.d. of 120 µm. The microbore needle had previously been blocked on several occasions. The larger bore needle used here eliminated that problem. The increased flow rate and shorter run times kept the TIC, peak list and abundances comparable to the initial study. All the other parameters were kept identical. All the potential significant markers from the initial, discovery set were reanalyzed for their performance in the second confirmation set using Student's T-test.
Chemical characterization of the replicating lipid biomarkers
After candidate biomarkers were found and confirmed significant by ESI-TOFMS, tandem MS (MS 2 ) was performed to fragment and characterize all validated biomarkers. Lipid markers were fragmented multi-channel analyzer (MCA) function was turned on resulting in summation of all 120 MS2 spectra together thus increasing signal to noise ratio.
For the Agilent 6530, sample injection was carried out at the flow rate of 10 µL /min. The capillary voltage was set to 3500 V. The drying gas flow rate and the temperature were 5 L/min and 300 0 C. MS2 spectra were collected from m/z 50-3000 and the spectral acquisition rate was 3 spectra /sec. Collision energies were optimized depending upon the precursor to obtain maximum fragmentation coverage.
Individual scans were summed using the add feature of the Mass Hunter program to obtain greater signal to noise. The targeted MS2 mode was used to isolate and fragment the precursor ion.
Exact mass studies were done while using a set of internal standards. Lipidmaps.org was used to tentatively determine the lipid class from the different possible classes for a particular precursor ion.
Furthermore, product ions, neutral losses, fragmentation patterns of standards or fragmentation patterns found in the literature, in conjunction with predicted fragments from the databases and predicted elemental compositions based on exact mass studies were compared with the actual observed fragments to determine the class and to evaluate the possible or probable components of the individual candidate markers.
Statistical Analyses
For comparisons between the cases and controls, the normalized intensities of all the peaks (abundance > 200 ion counts) in the first study were subjected to a two-tailed Student's t-test as an initial statistical comparison. A p-value <0.05 for any peak, was used to designate a potential biomarker. It is recognized that since the t-test statistic was performed for multiple peaks, separately, the true p-values are much larger than 0.05. Consequently, any candidate biomarker potentially may not be statistically significant between the cases and controls. However, using a one-at-a-time p-value calculation with a minimum threshold reduces the list of potential biomarkers. We augment this list by adding peaks that had low p-values close to 0.05 but greater than this threshold, resulting in a list of 45 potential biomarkers.
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Those peaks that continued to show differential expression, as measured by a p-value of less than 0.05 as determined from a one-at-a-time t-test in the second, independent set of specimens were considered highly likely to be biomarkers. Given the goal of generating panels of biomarkers, candidates with a p-value between 0.05 and 0.10 were also included because it is recognized that some markers may be selective for a subgroup within the broader diagnosis of preeclampsia and hence may be complementary to other markers. For this reason, they were considered in potential biomarker panels and were modeled to provide better sensitivities and specificities. Biomarker panel development employed a forward selection; leave one out, logistic regression analysis approach (23) (24) . In modeling the MS data, there were a few peaks in a small number of specimens for which intensities could not be determined due either to ion suppression by other nearby peaks or because of a sub-threshold abundance of a specific peak in that sample. To account for these missing values, the values for these peaks were estimated using multivariate imputation by chained equations. The method of chained equations used to predict the missing values was through predictive mean matching. This uses the values of the other samples to impute missing values, allowing for all peaks to still be used (25) . Using logistic regression analysis receiver operator characteristic curves were generated for these panels to allow for the determination of sensitivity (true positive) and specificity (1-true negative or false positive rate).
RESULTS
Serum lipid preeclamptic biomarkers in a discovery study
The hypothesis of this study was that there would be serum lipid biomarkers present at 12-14 wks pregnancy predictive of preeclampsia later in the same pregnancy. Using a global, serum lipidomic approach, the initial study of 27 controls and 29 cases found 45 candidate markers that were statistically or near statistically different in women who developed the disease compared with women who had uncomplicated pregnancies. The candidate markers are listed in Supplemental Table 2S .
Multi-marker panel development
Statistical modeling, using logistic regression analysis, was performed on the 23 replicating The overall AUC of this set is 0.88.
Chemical characterization of the validated serum lipid preeclamptic biomarkers
While absolute chemical structures of most lipids are not possible using MS, substantial chemical characterization is often provided by tandem MS fragmentation studies. Tandem MS studies were performed on all 23 confirmed serum lipid biomarkers. This provided lipid classes, exact mass studies suggested possible or probable elemental composition, fragments representing neutral losses suggested possible or probable structural components for most of the confirmed lipid biomarkers. The molecular features most consistent with the data are described in Table 2 . Collectively, our study and published literature suggest strongly that fragmentation patterns observed with PC lipid species follow predictable fragmentations.
Based on their fragmentation patterns, several of the lipid markers were categorized as PC lipids.
The MS 2 fragmentation spectrum for markers with m/z values of 734.6, 760.6, 784.6, 788.6, 796.6, 798.6, 810.6, 836.6 and 895.7 displayed a prominent peak at m/z 184.07 corresponding to a phosphocholine moiety. Their elemental compositions were predicted using exact mass studies and the fatty acyl constituents were assigned based on the neutral losses from the precursor ion with help from the Lipid MS predictor feature from LIPID MAPS and following the fragment patterns observed with PC standards.
The fragmentation spectrum of the marker with m/z 734.6 also displayed low abundance fragment ion with m/z 496.3 suggesting the presence of 16:0 fatty acyl chain (33) (Fig 4b) Due to the presence of a fragment ion at m/z 184.07 and a peak indicating water loss from the precursor, the marker with m/z 895.7 likely represents an oxidized sphingomyelin (SM) (odd M+H + having even neutral mass). Oxidized SM's have not been commonly studied using mass spectrometry (38).
Therefore, the structure for m/z 895.7 could not be predicted with certainty.
Tandem MS studies were also performed on a triacylglycerol standard, TG ( 
DISCUSSION
These studies tested the hypothesis that measurement of serum lipid biomarkers early in pregnancy would identify patients at risk for developing preeclampsia later in that pregnancy. Using a 'global' or indepth or 'shotgun' serum lipidomics approach, these studies suggest that there are predictive preeclampsia biomarkers.
Global serum lipidomic approaches are relatively new and have been applied to only a few clinical indications, e.g. Alzheimer's disease (43) (44) . To our knowledge they have not been previously applied to Preeclampsia, although there have been a few reports of altered cholesterol and triglyceride profiles in preeclampsia (45) (46) (47) .
Interest in lipids has increased as it has been recognized that lipids are more widely involved in cell regulatory pathways than previously thought. Lipids then may not only be altered in response to disease but it is possible that some circulating or cellular lipid species may mediate or contribute to aspects of disease. Given the uncertainties in the etiology and prediction of preeclampsia, there is interest in both by guest, on September 14, 2016 www.jlr.org
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developing better assessments of preeclampsia risk as well as better understanding the early changes that precede the fully manifest disorder.
Our approach led to the detection and confirmation of 23 unique lipid biomarkers for preeclampsia.
It is entirely possible that these circulating factors reflect the consequence of early disease, but some may have a more direct biological role. In the absence of an accepted animal model for preeclampsia, early events leading to this disease are poorly understood. A number of lipidomic biomarkers based on their lipid class and other potential characterization could be related to pathological processes linked to preeclampsia.
Thus, considering the changes in these specific biomarkers may be useful in providing biochemical information about early antecedents of this disease. Based on previous literature, some are at least suggestive. For example, among the several markers, the peak at m/z 383.3, was predicted to be an oxidized cholesterol (keto or epoxy). 7-ketocholesterol, which has the same mass, has been proposed to contribute to atherosclerosis (48) and vascular changes similar to atherosclerotic disease have been reported in preeclampsia (49) . This might explain the higher levels of this marker observed in women with later preeclampsia.
The candidate biomarkers having m/z values 734, 760, 784, 796, 810 and 836 were found to be higher in the serum of preeclamptic women and belong to the lipid class of glycerophosphocholines (PC).
Placental ischemia and apoptosis have been reported in preeclampsia, resulting in cell lysis with release of membrane constituents, including likely phosphatidylcholines, into the circulation (50) (51) . This might explain the higher levels of these markers in preeclamptic cases.
The marker with m/z 798 was predicted to be an oxidized (hydroxylated) PC ( reports of increased production of ROS in preeclampsia, which might explain the increased production of this marker in preeclamptic cases (52) .
Currently, there are no accepted biomarkers for predicting preeclampsia. A number of candidates have been proposed, especially pro-angiogenic and anti-angiogenic factors, and while they have repeatedly demonstrated changes in many women with established disease, they have shown poor sensitivity and specificity in predicting all forms of preeclampsia (11) (12) (13) . Therefore, there continues to be a need for predictive biomarkers of this disorder with more reliable sensitivities and specificities. The AUC values of 0.89 for two panels of markers detected in our study are substantially better than the previously reported values in the literature. The utility of these markers across two studies suggests these they should be considered of interest, especially given their being found early in the pregnancy and predicting events months later. The approach analyzed ~2,000 lipids but could also be carried out in the negative ion mode providing an even more comprehensive evaluation of serum lipids were it needed. This expansion of scope would likely provide additional useful lipid biomarkers for early diagnosis of preeclampsia. The current approach represents a versatile method requiring relatively simple specimen preparation and demonstrating adequate reproducibility. As such, it could be applied to the analysis of blood samples for potentially many other clinical targets.
While the current studies are suggestive, the specimens available were primarily from Caucasian subjects. It is recognized that additional studies are needed to determine whether the markers found are more universal in their application. Certainly, more serum lipidomic studies are needed to demonstrate clinical utility. Nevertheless, global serum lipidomics is a valuable and robust approach for the discovery and identification of lipid biomarkers for disease and may have provided useful predictive markers for preeclampsia. 
